ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0641 • ACR Convergence 2024

    Predictive Validity of Coronary Artery Calcium Scoring in Low Risk Systemic Lupus Erythematous Patients

    Katherine Chakrabarti1, Apurba Chakrabarti2, Emily Lewis2 and William McCune3, 1University of Michigan, Ann Arbor, MI, 2University of Michigan Hospital, Ann Arbor, MI, 3U Michigan, Ann Arbor, MI

    Background/Purpose: Traditionally, a coronary artery calcium (CAC) score of zero is associated with low rates (0.1-0.2% annualized risk) of major adverse cardiovascular outcomes (MACE). While…
  • Abstract Number: 0645 • ACR Convergence 2024

    Mortality and Ethnicity in Adults with Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Analysis

    Samir Patel1, Zijing Yang1, deepak Nagra1, Maryam Adas2, Mark Russell1, Sam Norton1, Chris Wincup3, James Galloway4, Kate Bramham2 and Patrick Gordon5, 1King's College London, London, England, United Kingdom, 2King's College London, London, United Kingdom, 3King's College Hospital, London, United Kingdom, 4Centre for Rheumatic Diseases, King's College London, London, United Kingdom, 5nhs, London, United Kingdom

    Background/Purpose: Ethnicity and health outcomes are intrinsically interrelated, although mechanisms are complex. Systemic lupus erythematosus (SLE) is a disease with higher incidence in non-White populations…
  • Abstract Number: 0634 • ACR Convergence 2024

    Clinical Relevance of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) in Predicting Lupus Outcomes: A 5-Year Longitudinal Cohort Study

    Hyemin Jeong1, Ji-Hyoun Kang1, Sung-Eun Choi2, Dong-Jin Park3 and Shin-Seok Lee4, 1Chonnam National University Hospital, Gwangju, South Korea, 2Chonnam National University Medical School & Hospital, Gwangju, South Korea, 3Chonnam National University Medical School and Hospital, Gwangju, South Korea, 4Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, KR, Gwangju, Republic of Korea

    Background/Purpose: Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) is a newly developed tool for assessing disease activity in SLE patients. Despite external validation in diverse…
  • Abstract Number: 0567 • ACR Convergence 2024

    Alteration of JAK-STAT Signaling in an Axial Spondyloarthritispatient with TYK2 Variants

    Pankaj Sharma1, Fatemeh Navid1, Norman Watts1, Stephen Brooks2 and Robert Colbert2, 1National Institutes of Health, Bethesda, MD, 2NIH/NIAMS, Bethesda, MD

    Background/Purpose: Tyrosine kinase 2 (TYK2) is a member of the Janus kinase family that associates with the cytoplasmic domain of type I/II cytokine receptors and…
  • Abstract Number: 0629 • ACR Convergence 2024

    Evaluating the Concordance Between SRI4 and BICLA Using Placebo Data from Randomized Controlled Trials of Patients with Active Systemic Lupus Erythematosus

    Anca Askanase1, Edward Vital2, Oliver Meier3, Armando Turchetta4, Huiyan (Ashley) Mao4, Justine Maller5, Jorge A. Ross Terres6 and Maria Dall'Era7, 1Columbia University Medical Center, New York, NY, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland, 4Hoffmann-La Roche Ltd, Mississauga, Canada, 5Genentech, Inc,, San Francisco, CA, 6Genentech, Inc,, San Francisco, 7UCSF, Corte Madera, CA

    Background/Purpose: British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and Systemic Lupus Erythematosus Responder Index 4 (SRI4) responses are the most common primary…
  • Abstract Number: 0610 • ACR Convergence 2024

    Clinical Evaluation on IFI44L Gene Methylation Detection for Diagnosis of Systemic Lupus Erythematosus by Methylation Sensitive High Resolution Melting (MS-HRM)

    Xiaoping hong and liancheng lin, The Second Clinical Medical College of Jinan University, Shenzhen, China (People's Republic)

    Background/Purpose: To evaluate the clinical effectiveness of IFI44L gene methylation detection for the diagnosis of Systemic Lupus Erythematosus (SLE) by MS-HRM, to determine  the relative…
  • Abstract Number: 0639 • ACR Convergence 2024

    Delayed Diagnosis in Systemic Lupus Erythematosus

    Romina Nieto1, Lucia Hernandez2, Nidia Noemí Merás3, Bordón Florencia Juliana4, Cintia Otaduy5, Lucila Garcia6, Rosa Serrano Morales7, Nicolás Pérez8, Micaela A. Cosatti9, Ana Carolina Montandon10, Gustavo Flores Chapacais11, Laissa C. Alves Alvino12, Emily Figuereido Neves13, Eloisa Bonfa14, Alexis Bondi Peralta15, Loreto Massardo16, Andrés Cadena Bonfanti17, Andrés Hormaza18, José Martínez19, Olga Lidia Vera Lastra20, Hilda Fragoso-Loyo21, ⁠Yaneli Juárez-Vicuña22, Diana Fernandez23, Patricia Langjarth24, Maria Teresa Martinez de Filartiga25, Manuel Ugarte-Gil26, Carlos Alejandro Loayza Flores27, Teresandris Polanco28, Maria Belen Lecumberri29, Álvaro Danza30, Carlos Enrique Toro-Gutierrez31, Urbano Sbarigia32, Ashley Orillion33, Federico Zazzetti34, Graciela Alarcon35, Bernardo Pons-Estel2 and Guillermo Pons-Estel36, and Grupo Latino Americano de Estudio del Lupus (GLADEL), 1Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, 2Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, 3Hospital Italiano de Córdoba, Cordoba, Argentina, 4Hospital Privado Universitario de Córdoba, Córdoba, Argentina, 5Hospital Córdoba, Cordoba, Spain, 6Servicio de Reumatología del HIGA San Martín, La Plata, Argentina, 7Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, 8Instituto de Investigaciones Médicos Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, 9CEMIC Centro de Educación Médica e Investigaciones Clínicas ''Norberto Quirno'' CABA, CABA, Argentina, 10Hospital das Clinicas, Universidad Federal de Goias, Goias, Brazil, 11Rheumatology Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 12Hospital Universitario Pedro Ernesto, UERJ, Rio de Janeiro, Brazil, 13Hospital da Clinicas de Sao Paulo, São Paulo, SP, Brazil, 14Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 15Hospital del Salvador, Santiago, Chile, 16Centro de Biología Celular y Biomedicina CEBICEM, Facultad de Medicina y Ciencias Universidad San Sebastián, Santiago, Chile, 17Universidad Simon Bolivar, Barranquilla, Colombia, 18Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, 19Rheumatology Service, Luís Vernaza Hospital, Guayaquil, Ecuador, 20División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, 21Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, 22Instituto Nacional de Cardiología Ignacio Chávez, Departamento de Inmunología, Investigador en Ciencias Médicas C, Mexico City, Mexico, 23Member of GLADEL, Rosario, Argentina, 24Hospital de Clínicas I, Asunción, Paraguay, 25Dpto de Reumatología Hospital de Clínicas. Facultad de Ciencias medicas.Universidad Nacional de Asunción, Asuncion del Paraguay, Paraguay, 26Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas. Universidad Científica del Sur. Lima. Perú Servicio de Reumatología. Hospital Guillermo Almenara Irigoyen-EsSalud, Lima, Peru, 27Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, 28Hospital Docente Padre Billini, Santo Domingo, Dominica, 29Hospital Señor del Milagro, Salta, Argentina, 30Médica Uruguaya Corporación de Asistencia Médica (MUCAM). Clínica Médica - Facultad de Medicina - UdelaR, Montevideo, Uruguay, 31Reference Center for Osteoporosis & Rheumatology, Cali, Colombia, 32Johnson & Johnson Innovative Medicine, Brussels, Belgium, 33Johnson & Johnson Innovative Medicine, Spring House, PA, PA, 34Johnson & Johnson Innovative Medicine, Horsham, PA, PA, 35The University of Alabama at Birmingham, Oakland, CA, 36Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina

    Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease of unknown etiology. Diagnosis is often delayed because it frequently mimics symptoms of other diseases;…
  • Abstract Number: 0425 • ACR Convergence 2024

    Use of bDMARDs During Pregnancy After Preconceptional Counseling in Spanish Patients with Rheumatic Diseases

    Antia Garcia Fernandez1, Fernando Rengifo-Garcia1, Raquel Senosiain-Echarte1, Miguel Álvaro Navidad1, Miguel Angel Gonzalez-Gay2 and Juan Antonio Martínez - López1, 1Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, 2University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain

    Background/Purpose: Current recommendations advocate maintaining pregnancy-compatible bDMARDs during pregnancy (mainly TNF inhibitors) and monitoring disease activity before conception to improve disease and pregnancy outcomes. Recently,…
  • Abstract Number: 0644 • ACR Convergence 2024

    Scoping Literature Review to Identify Candidate Domains for the SLE OMERACT Core Outcome Set

    Wils Nielsen1, Fadi Kharouf2, Carolina Munoz-Grajales3, Aarabi Thayaparan4, Melanie Anderson5, Lee Simon6, Maya Desai7, Ioannis Parodis8, Alfred Kim9, Yvonne Enman10, Kathleen Bingham11, Dennisse Bonilla11, Julian Thumboo12, Marta Mosca13, Martin Aringer14, Eric Morand15, Ian Bruce16, Vibeke Strand17 and Zahi Touma4, 1University of Toronto, Markham, ON, Canada, 2University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, 3UHN/TWH, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada, 5The Institute for Education Research, Library and Information Services, University Health Network, Toronto, ON, Canada, 6SDG LLC, West Newton, MA, 7Ontario College of Art and Design University, Toronto, ON, Canada, 8Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, 9Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, 10Karolinska Institutet, Stockholm, Sweden, 11University Health Network, Toronto, ON, Canada, 12Singapore General Hospital, Singapore, Singapore, 13University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, 14University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, 15School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, 16Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, 17Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA

    Background/Purpose: The Outcome Measures in Rheumatology (OMERACT) Systemic Lupus Erythematosus (SLE) Working Group was re-established in 2018 to update the SLE Core Outcome Set (COS)…
  • Abstract Number: 0437 • ACR Convergence 2024

    Describing Maternal Outcomes Among Veterans with a History of Systemic Lupus Erythematosus and Rheumatoid Arthritis

    Deirdre Quinn1, Florentina Sileanu1, Gregory Procario1, Shannon Mitchell1 and Mehret Birru Talabi2, 1VA Pittsburgh Healthcare System, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Veterans who utilize Department of Veterans Affairs (VA) maternity benefits, nearly half (42%) of whom represent racial or ethnic minority groups, have a high…
  • Abstract Number: 0559 • ACR Convergence 2024

    Predicting Disease Flares in Axial Spondyloarthritis Using Machine Learning in the METEOR-SpA Registry

    Diego Benavent1, Victor Fanjul2, Sytske Anne Bergstra3, Floris van Gaalen4, Maxime Dougados5, Umut Kalyoncu6, Denis Poddubnyy7, Clementina López Medina8, Konstantinos Parperis9, David Vega-Morales10, Desiree van der Heijde11 and Victoria Navarro Compán12, 1Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, 2Savana Research, Madrid, 3LUMC, Leiden, Netherlands, 4LUMC, Leiden, Zuid-Holland, Netherlands, 5Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, 6Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 7Charite-Universitatsmedizin Berlin, Berlin, Germany, 8Reina Sofia University Hospital, Cordoba, Spain, 9University of Cyprus Medical School, Nicosia, Cyprus, 10Instituto Mexicano del Seguro Social, Monterrey, México, Monterrey, Mexico, 11Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, 12La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain

    Background/Purpose: Patients with axial spondyloarthritis (axSpA) frequently experience unforeseen disease flares that impact their quality of life. Identification of patients with high risk of flares…
  • Abstract Number: 0619 • ACR Convergence 2024

    Prevalence and Factors Predicting Hemophagocytic Lymphohistiocytosis in Hospitalized Patients with Systemic Lupus Erythematosus

    OKEOGHENE AKPOIGBE1, BETTINA ESCOLANO2, ENOCH J ABBEY2 and Amanda Sammut3, 1New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, NY, 2New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, 3New York City Health and Hospitals/Harlem. Rheumatology Department, Chappaqua, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) complicated with hemophagocytic lymphohistiocystosis (HLH) can be life-threatening with mortality as high as 9.9%-10.5%. Estimates of the prevalence of HLH…
  • Abstract Number: 0638 • ACR Convergence 2024

    Soluble TNF RII in Lupus Nephritis as a Biomarker of Disease Activity and Treatment Response

    Ranjan Gupta1, Sonam Rajput2, Jayanth Kumar2 and Dipendra K Mitra2, 1All India Institute of Medical Sciences, New Delhi, Delhi, India, 2All India Institute of Medical Sciences, New Delhi, New Delhi, India

    Background/Purpose: Lupus Nephritis (LN) affects almost 60-70% patients of Systemic Lupus Erythematosus (SLE). Conventional markers of renal involvement i.e. proteinuria and renal biopsy have limitations…
  • Abstract Number: 0646 • ACR Convergence 2024

    Chart Audit of over 1,000 SLE Patients Reveals Biologic Treatment Choice Driven by Disease Manifestations

    Maxine Yarnall1, Ryan Rex2 and Sawyer May1, 1Spherix Global Insights, Exton, PA, 2Spherix Global Insights, Chester Springs, PA

    Background/Purpose: To better understand how US rheumatologists utilize biologics in the management of SLE, especially among those with cutaneous manifestations. No medication is currently FDA-approved…
  • Abstract Number: 0548 • ACR Convergence 2024

    Associations and Impact of Kinesiophobia on Patient Reported Outcomes and Performance-based Mobility Measures in Patients with Axial Spondyloarthritis

    David Kiefer1, Juergen Braun2, Uta Kiltz3, Niklas Kolle1, Lucia Schneider1, Ioana Andreica4, Bjoern Buehring5, Philipp Sewerin6, Imke Redeker7, Styliani Tsiami8, Susanne Herbold9 and Xenofon Baraliakos8, 1Ruhr-Universität Bochum; Rheumazentrum Ruhrgebiet, Herne, Germany, 2Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, 3Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, 4Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 5Bergisches Rheuma-Zentrum Wuppertal; Ruhr-Universität Bochum, Wuppertal, Germany, 6Ruhr-Universität Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany, 7Ruhr Universität Bochum, Bochum, Germany, 8Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 9Rheumazentrum Ruhrgebiet, Herne, Herne, Germany

    Background/Purpose: Kinesiophobia, defined as the fear of movement, poses a significant barrier to effective rehabilitation, functional recovery, and adequate physical activity. To investigate the impact…
  • « Previous Page
  • 1
  • …
  • 352
  • 353
  • 354
  • 355
  • 356
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology